Page 6 - Aytu Biopharma Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aytu biopharma daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aytu Biopharma Daily Today - Breaking & Trending Today

Aytu BioPharma, Inc.: Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of ....

University Of Southern California , United States , Aytu Biopharma , Mark Oki , Vivian Liu , Apricus Biosciences , Josh Disbrow , University Of California , Fastrack Pharmaceuticals Inc , Innovus Pharmaceuticals Inc , Audit Committee For Thermogenesis Holdings Inc , Corporate Governance Committee , Cesca Therapeutics Inc , Drug Administration , European Commission , Oxonc Services Company , Nexmed Inc , Exchange Commission , Head Of Corporate Affairs , Aytu Biopharma Inc , Securities Exchange , Corporate Affairs , Corporate Governance , Chief Executive Officer , Chief Financial Officer , Innovus Pharmaceuticals ,

Aytu BioPharma (NASDAQ:AYTU) Upgraded by Zacks Investment Research to "Hold"

Aytu BioPharma (NASDAQ:AYTU – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. […] ....

United States , Aytu Biopharma , Morgan Stanley , Geode Capital Management , Zacks Investment Research , Blackrock Inc , Renaissance Technologies , Aytu Bioscience Inc , Marshall Wace , Cantor Fitzgerald , Aytu Biopharma Inc , Get Rating , Capital Management , Nasdaq Aytu ,

Aytu BioPharma (NASDAQ:AYTU) Downgraded to Sell at Zacks Investment Research

Aytu BioPharma (NASDAQ:AYTU – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. […] ....

United States , Aytu Biopharma , Morgan Stanley , Geode Capital Management , Zacks Investment Research , Blackrock Inc , Renaissance Technologies , Aytu Bioscience Inc , Marshall Wace , Cantor Fitzgerald , Aytu Biopharma Inc , Aytu Biopharma Company Profile Get Rating , Get Rating , Capital Management , Biopharma Company Profile , Nasdaq Aytu ,

Aytu BioPharma, Inc.: Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome

ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food ....

United States , Aytu Biopharma , Chelcie Lister , Josh Disbrow , Drug Administration , Exchange Commission , Strategic Communications , Aytu Biopharma Inc , Securities Exchange , European Medicines Agency , Fast Track , Vascular Ehlers Danlos Syndrome , Chief Executive Officer , Orphan Drug , New Drug , Full Prescribing Information , Ehlers Danlos Syndrome , European Medicines , Securities Act , Securities Exchange Act , Risk Factor , Quarterly Reports ,

Aytu BioPharma, Inc.: Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT

ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued ....

United States , Aytu Biopharma , Chelcie Lister , Josh Disbrow , National Pregnancy Registry For Psychostimulants , Drug Administration , Trademark Office , Exchange Commission , Strategic Communications , Aytu Biopharma Inc , Securities Exchange , European Medicines Agency , Drug Products , Therapeutic Equivalence , New Drug Application , United States Patent , Orange Book , Hyperactivity Disorder , National Pregnancy Registry , Full Prescribing Information , Ehlers Danlos Syndrome , Orphan Drug , European Medicines , Securities Act , Securities Exchange Act , Risk Factor ,